Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Investigación de adaptaciones metabólicas y psicológicas en un ensayo clínico (IMPACT)

16 de noviembre de 2026 actualizado por: Leonard Epstein, State University of New York at Buffalo

Efecto del momento de la comida y los cambios en la dieta en los factores metabólicos y de comportamiento involucrados en la paradoja de la obesidad de la inseguridad alimentaria

This study aims to explore how food insecurity, a lack of consistent access to enough food, may lead to changes in the body that make it harder to lose weight. The investigators are testing whether providing women experiencing food insecurity with a stable, healthy, and personalized meal plan can improve their metabolism and reduce their motivation to eat unhealthy foods. The hypothesis is that addressing food insecurity with a predictable diet can lower a person's respiratory quotient (a measure of how the body uses energy), promote fat burning, and improve overall health. This research will improve the understanding for how food insecurity contributes to obesity and may lead to better solutions for managing weight in individuals facing these challenges.

Descripción general del estudio

Descripción detallada

Women who experience food insecurity have unpredictable access to food and often miss meals and go hungry, but paradoxically are at a 50% greater risk for developing obesity than women who are food secure. This is due in part to metabolic and behavioral factors involved in food insecurity. Research suggests unpredictable access to food is associated with: 1) a high respiratory quotient (RQ) indicative of substrate oxidation that favors storage of fat and burning of carbohydrates; 2) an increase in fuel efficiency and a reduced thermic effect of food (TEF); 3) higher relative reinforcing efficacy of food (RREFOOD), due in part to periodic food deprivation that results from unpredictable access to food and being hungry, and 4) a short temporal window that involves making decisions that focus on meeting immediate versus long-term goals, as assessed by delay discounting (DD). While people with food insecurity and obesity should modify their diet, an RQ that favors storage of fat coupled with a reduced TEF, high RREFOOD and high DD may compromise the effects of traditional dietary approaches to weight loss. The goal of this pilot study is to examine the effects of providing a personalized, stable, predictable, low carbohydrate, low glycemic index, high protein, low energy dense diet on changes in metabolic and behavioral factors that characterize low-income women with food insecurity who have obesity, using a novel stepped wedge design. This work extends our research on behavioral and metabolic factors involved in food insecurity, and will provide strong pilot data for a randomized, controlled trial of a novel dietary approach that target factors involved in food insecurity and obesity that can improve weight control and reduce cardiometabolic risk factors. The investigators expect to screen at least 60 women, with an estimated screen failure rate of 80%. A goal for this pilot project is to provide effect sizes for future studies. The sample size was determined based on feasibility constraints, with the understanding that these results will serve as pilot data for a larger, fully powered randomized controlled trial.

Tipo de estudio

Intervencionista

Inscripción (Actual)

12

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • New York
      • Buffalo, New York, Estados Unidos, 14221
        • Farber Hall G56

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 45 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Woman between the ages of 18-45.
  • Premenopausal.
  • Obese (BMI ≥ 30).
  • Diagnosed with prediabetes (HbA1c: 5.7%-6.4%).
  • Experiencing food insecurity (score of 2-6 on the six-item food insecurity questionnaire).
  • Income below 300% of the household federal poverty threshold.
  • Lives alone.

Exclusion Criteria:

  • Actively planning to become pregnant (e.g., individuals trying to conceive or undergoing fertility treatment, based on self-report).

  • Delivered a baby within the past 6 months (self-report).

  • Non-ambulatory (e.g., individuals unable to walk independently or requiring a wheelchair for mobility).

  • Intellectual impairment that would impact treatment adherence.

  • Unmanaged mood disorders, substance use disorders, personality disorders, or a history of eating disorders, including:

    • Generalized anxiety disorder.
    • Depression.
    • Alcohol dependence.
    • Schizophrenia.
    • Anorexia nervosa, bulimia, or binge eating disorder within the past 6 months.
  • Recent weight loss exceeding 5% of body weight within the past 6 months (self-report).

  • Food allergies to study-related foods, including dairy, soy, nuts, or gluten.

  • History of bariatric surgery or GLP-1 agonist use (self-report).

  • Inability to read or write in English (self-report).

  • Planned relocation out of the study area during the study timeframe (self-report).

  • Uncontrolled diabetes (HbA1c > 9%) or hypertension (blood pressure > 160/100 mmHg), based on self-report or screening visit measurements.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Sin intervención: Control phase

During this phase, participants are told to maintain typical behaviors and not change any normal patterns of activity/eating.

Experimental: Treatment phase

There are two components to the treatment:

Food provisioning: The food provisioning component will consist of bi-weekly home deliveries of three meals a day. The number of calories in the provided meals for each day will be personalized based on each participant's resting metabolic rate. Caloric targets for each participant will be 20% of TDEE as this translates to ~1-2 pounds of weight loss per week. Diets composition will also be tailored to help improve TEF and RQ.

Behavioral Skills Training: This will be based on an evidence-based behavioral weight-loss program developed in our lab. This treatment has shown clinically significant weight loss with positive effects sustained over 10-years. The specific includes lessons on self-monitoring, developing alternatives to foods, meal-planning, goal setting, episodic future thinking, physical activity, and self-reinforcement.

7 sessions including: Hunger and fullness, eating on a budget, traffic light eating plan, menu planning, creating alternatives to food, financial planning, and changing the environment.

3 meals a day consisting of low energy dense, nutrient rich, ready to eat, low GI, foods delivered to the participants' homes.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in body weight
Periodo de tiempo: Through study completion, an average of 25 weeks

measured in kgs using a weight scale.

Through study completion, an average of 25 weeks
change in HBA1C
Periodo de tiempo: Through study completion, an average of 25 weeks.

measured via a finger-prick blood sample analyzed using a point-of-care device

Through study completion, an average of 25 weeks.
Change in respiratory quotient
Periodo de tiempo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
change in TEF
Periodo de tiempo: Through study completion, an average of 25 weeks.

will be measured in morning fasting state using the Breezing Pro, an FDA approved device for portable metabolic measures

Through study completion, an average of 25 weeks.
Change in delay discounting
Periodo de tiempo: Through study completion, an average of 25 weeks.

will be measured using the adjusting amount delay discounting task that presents participants with choices between a fraction of the total delayed amount of money now or the full amount ($100 &/ $1000) at a future delayed time for five different periods from 30 days, 180 days, 365 days (1 year), 1095 days (3 years), 1825 days (5 years) (order randomized).

Through study completion, an average of 25 weeks.
Change in RRE
Periodo de tiempo: Through study completion, an average of 25 weeks.

RRE will be assessed through a survey that will use participants' preferred snack foods that are classified as either hyperpalatable or healthy. Scores have no fixed minimum or maximum, as they are determined by the highest ratio completed before the participant stops working for the food reward. Higher scores indicate greater reinforcing efficacy and a stronger motivational drive for the food reward, which is considered a worse outcome in this context.

Through study completion, an average of 25 weeks.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
change in stress
Periodo de tiempo: Through study completion, an average of 25 weeks.

measured using the Perceived Stress Scale. The Perceived Stress Scale is a validated 10-item questionnaire that measures the perception of stress over the past month. Scores range from 0 to 40, where higher scores indicate greater perceived stress and worse outcomes.

Through study completion, an average of 25 weeks.
change in physical activity
Periodo de tiempo: Through study completion, an average of 25 weeks.

measured using a Fitbit activity monitor

Through study completion, an average of 25 weeks.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de julio de 2025

Finalización primaria (Actual)

30 de junio de 2026

Finalización del estudio (Actual)

30 de septiembre de 2026

Fechas de registro del estudio

Enviado por primera vez

17 de enero de 2025

Primero enviado que cumplió con los criterios de control de calidad

23 de enero de 2025

Publicado por primera vez (Actual)

30 de enero de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de enero de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The investigators plan to share de-identified individual participant data (IPD) with other researchers to promote transparency, reproducibility, and the advancement of scientific knowledge.

Marco de tiempo para compartir IPD

The IPD and supporting information (Study Protocol, SAP, ICF, and Analytic Code) will be made available no later than 12 months after the publication of the primary study results or 12 months after the final study completion date (November 1, 2025), whichever comes first. Therefore, the anticipated start date for data availability is November 1, 2026. The IPD and supporting information will remain available for a period of 5 years from the start date, allowing sufficient time for secondary analyses and collaborative research. The anticipated end date is November 1, 2031.

Criterios de acceso compartido de IPD

Qualified Researchers: Access will be granted to researchers affiliated with academic, non-profit, or governmental institutions conducting non-commercial research. Researchers must demonstrate a legitimate scientific purpose for using the data.

Individual Participant Data (IPD):

De-identified data for all primary and secondary outcome measures (e.g., respiratory quotient, thermic effect of food, body weight, relative reinforcing value of food, and delay discounting).

Accompanying metadata and codebooks for proper interpretation of the data.

Supporting Information:

Study Protocol: Detailed description of the study design and methodology. Statistical Analysis Plan (SAP): Comprehensive explanation of the planned statistical analyses for all outcomes.

Informed Consent Form (ICF): Template of the consent form used during the study.

Analytic Code: Scripts used for data cleaning and statistical analyses, enabling reproducibility of results.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir